BMJ  2005;331:1013-1015 (29 October), doi:10.1136/bmj.331.7523.1013

Education and debate

Problems in assessing rates of infection with methicillin resistant Staphylococcus aureus

¹ MRC Biostatistics Unit, Institute of Public Health, Cambridge CB2 2SR david.spiegelhalter@mrc-bsu.cam.ac.uk

Chance variability makes it impossible to assess reliably whether individual trusts are meeting annual targets for reduction in the risk of MRSA infection

The first 150 words of the full text of this article appear below.

Introduction

One of the core standards set by the Department of Health is to achieve year on year reductions in rates of infection with methicillin resistant Staphylococcus aureus (MRSA).¹ This was clarified in November 2004 by the (then) health secretary John Reid, who said that he expected "MRSA bloodstream infection rates to be halved in our hospitals by 2008," that "NHS Acute Trusts will be tasked with achieving a year on year reduction,"² and that such a target was "achievable, measurable, and not too burdensome." Several problems can arise, however, when measuring change in rates, particularly when the observed number of events is fairly low. These include the effects of chance variability, regression to the mean, and low power to detect genuine underlying changes. These problems are accentuated with an infectious disease, since cases tend to cluster and hence rates are "over-dispersed" relative to chance variation.³ So how should we interpret . . . [Full text of this article]

What is the target?

Role of chance

Improving measures of performance

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Improvement targets for C difficile must be valid

M A Cooper and P M Hawkey
BMJ 2007 334: 709. [Extract] [Full Text] [PDF]

Improving surveillance of MRSA bacteraemia: The tragedy of targets

Anthony P Morton
BMJ 2005 331: 1143-1144. [Extract] [Full Text]

Targets for trusts' MRSA infection rates need clarifying
BMJ 2005 331: 0. [Full Text]

Complicated questions—difficult answers

Jane Smith
BMJ 2005 331: 0. [Extract] [Full Text] [PDF]

Improving surveillance of MRSA bacteraemia

Georgia Duckworth and Andr Charlett
BMJ 2005 331: 976-977. [Extract] [Full Text] [PDF]

Statistic Notes: Regression towards the mean

J M Bland and D G Altman
BMJ 1994 308: 1499. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Hurley, J. C. (2008). Profound effect of study design factors on ventilator-associated pneumonia incidence of prevention studies: benchmarking the literature experience. J Antimicrob Chemother 61: 1154-1161 [Abstract] [Full text]  
• Harbarth, S., Fankhauser, C., Schrenzel, J., Christenson, J., Gervaz, P., Bandiera-Clerc, C., Renzi, G., Vernaz, N., Sax, H., Pittet, D. (2008). Universal Screening for Methicillin-Resistant Staphylococcus aureus at Hospital Admission and Nosocomial Infection in Surgical Patients. JAMA 299: 1149-1157 [Abstract] [Full text]  
• Cooper, M A, Hawkey, P M (2007). Improvement targets for C difficile must be valid. BMJ 334: 709-709 [Full text]  
• Morton, A. P (2005). Improving surveillance of MRSA bacteraemia: The tragedy of targets. BMJ 331: 1143-1144 [Full text]  
• Duckworth, G., Charlett, A. (2005). Improving surveillance of MRSA bacteraemia. BMJ 331: 976-977 [Full text]  

Rapid Responses:

Read all Rapid Responses

The Tragedy of Targets

Anthony P Morton
bmj.com, 1 Nov 2005 [Full text]

Meeting targets for MRSA

Martin Bland
bmj.com, 3 Nov 2005 [Full text]

Size matters

S. Michael Crawford
bmj.com, 7 Nov 2005 [Full text]

Using measures of MRSA rates to drive improvement

Anne Maclaren
bmj.com, 13 Jan 2006 [Full text]

Online poll

Find out more >>